- Home
- MTEN vs NRSN Comparison
MTEN vs NRSN Comparison
Compare MTEN & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTEN | NRSN |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MTEN | NRSN |
|---|---|---|
| Price | $0.85 | $2.39 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $78.50 |
| AVG Volume (30 Days) | ★ 1.1M | 16.1K |
| Earning Date | 10-30-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $0.25 |
| 52 Week High | $9.52 | $7.50 |
Technical Indicators
Market Signals| Indicator | MTEN | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 35.69 |
| Support Level | $0.85 | $0.63 |
| Resistance Level | $1.25 | $7.50 |
| Average True Range (ATR) | 0.09 | 0.41 |
| MACD | -0.01 | -0.34 |
| Stochastic Oscillator | 11.88 | 1.32 |
Price Performance
Historical ComparisonAbout MTEN Mingteng International Corporation Inc. Ordinary Shares
Mingteng International Corp Inc operates as an automotive mold developer and supplier in China. It provides an extensive product lineup, including casting molds for turbocharger systems, braking systems, steering and differential systems, and other automotive system parts. Besides, it also produces molds for new energy electric vehicle motor drive systems, battery pack systems, and engineering hydraulic components, which are widely used in the automobile, construction machinery, and other manufacturing industries.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.